Germany's CureVac wins new vaccine funding from Gates Foundation

(Reuters) - German biotech firm CureVac has secured more financial backing for vaccine development projects from its investor the Bill & Melinda Gates Foundation, working on jabs to prevent malaria and influenza. The research projects will run until 2020 with the aim to find drug candidates based on CureVac’s synthetic messenger RNA, or mRNA technology, that may at later stages be tested on hum...